<DOC>
	<DOCNO>NCT00171249</DOCNO>
	<brief_summary>This extension II study allow follow-up disease treatment imatinib mesylate allow patient continue receive imatinib mesylate .</brief_summary>
	<brief_title>An Extension Study Safety Anti-leukemic Effects Imatinib Mesylate Adult Patients With Ph + Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Successful completion CSTI571A0109E1 study Written inform consent extension CSTI571A0109E2 none Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Philadelphia Chromosome</keyword>
	<keyword>Accelerated phase</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>